Lisa L. Cunningham

Lisa L. Cunningham

Auto-generated profile, based on publicly available information

Lisa L. Cunningham

Laboratory of Hearing Biology and Therapeutics, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
LCLisa L Cunningham
Lisa L Cunningham
DTDebara L Tucci
Debara L Tucci
Half of adults in their seventh decade and 80% who are at least 85 years old have hearing loss. Understanding the auditory system and the diseases affecting each component of it allows clinicians to address the problem and refer patients to appropriate personnel.

1 June 2003 in Journal of the Association for Research in Otolaryngology
Verified
Journal Article
Closed access
PDF file
JHJulie A. Harris
Julie A. Harris
ACAlan G. Cheng
Alan G. Cheng
LCLisa L. Cunningham
Lisa L. Cunningham
GMGlen MacDonald
Glen MacDonald
DRDavid W. Raible
David W. Raible
EREdwin W Rubel
Edwin W Rubel

21 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAndrew M. Breglio
Andrew M. Breglio
ARAaron E. Rusheen
Aaron E. Rusheen
ESEric D. Shide
Eric D. Shide
KFKatharine A. Fernandez
Katharine A. Fernandez
KSKatie K. Spielbauer
Katie K. Spielbauer
LCLisa L. Cunningham
Lisa L. Cunningham
Cisplatin chemotherapy causes permanent hearing loss in 40–80% of treated patients. It is unclear whether the cochlea has unique sensitivity to cisplatin or is exposed to higher levels of the drug. Here we use inductively coupled plasma mass spectrometry (ICP-MS) to examine cisplatin pharmacokinetics in the cochleae of mice and humans. In most organs cisplatin is detected within one hour after injection, and is eliminated over the following days to weeks. In contrast, the cochlea retains cisplatin for months to years after treatment in both mice and humans. Using laser ablation coupled to ICP-MS, we map cisplatin distribution within the human cochlea. Cisplatin accumulation is consistently high in the stria vascularis, the region of the cochlea that maintains the ionic composition of endolymph. Our results demonstrate long-term retention of cisplatin in the human cochlea, and they point to the stria vascularis as an important therapeutic target for preventing cisplatin ototoxicity.

7 April 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
TWTian Wang
Tian Wang
Renjie ChaiRenjie Chai
Renjie Chai
GKGrace S. Kim
Grace S. Kim
NPNicole Pham
Nicole Pham
LJLina Jansson
Lina Jansson
ACAlan G. Cheng
Alan G. Cheng
Recruitment of endogenous progenitors is critical during tissue repair. The inner ear utricle requires mechanosensory hair cells (HCs) to detect linear acceleration. After damage, non-mammalian utricles regenerate HCs via both proliferation and direct transdifferentiation. In adult mammals, limited transdifferentiation from unidentified progenitors occurs to regenerate extrastriolar Type II HCs. Here we show that HC damage in neonatal mouse utricle activates the Wnt target gene Lgr5 in striolar supporting cells. Lineage tracing and time-lapse microscopy reveal that Lgr5+ cells transdifferentiate into HC-like cells in vitro. In contrast to adults, HC ablation in neonatal utricles in vivo recruits Lgr5+ cells to regenerate striolar HCs through mitotic and transdifferentiation pathways. Both Type I and II HCs are regenerated, and regenerated HCs display stereocilia and synapses. Lastly, stabilized ß-catenin in Lgr5+ cells enhances mitotic activity and HC regeneration. Thus Lgr5 marks Wnt-regulated, damage-activated HC progenitors and may help uncover factors driving mammalian HC regeneration.

1 December 2005 in Current Opinion in Otolaryngology & Head and Neck Surgery
Verified
Journal Article
Closed access
ACAlan G Cheng
Alan G Cheng
LCLisa L Cunningham
Lisa L Cunningham
EREdwin W Rubel
Edwin W Rubel
Sensory hair cells are mechanotransducers of the inner ear that are essential for hearing and balance. Hair cell death commonly occurs following acoustic trauma or exposure to ototoxins, such as the aminoglycoside antibiotics and the antineoplastic agent cisplatin. Loss of these inner ear sensory cells can lead to permanent sensorineural hearing loss, balance disturbance, or both. Currently, the only effective clinical intervention is prevention from exposure to known ototoxic insults. To help improve therapeutic strategies, a better understanding of the molecular mechanisms underlying hair cell degeneration is required. Current knowledge of these cell death mechanisms and potential therapeutic targets are discussed in this review. Studies have shown that caspase-9 and caspase-3 are key mediators of hair cell death induced by noise, aminoglycosides, and cisplatin. The Bcl-2 family consists of a group of proapoptotic and antiapoptotic molecules that act upstream of and regulate caspase activation. Recent studies have shed light on the roles of molecules acting more upstream, including mitogen-activated protein kinases and p53. The mechanisms of sensory hair cell degeneration in response to different ototoxic stimuli share a final common pathway: caspase activation. Inhibition of caspases prevents or delays hair cell death and may preserve hearing/balance function. Inhibition of mitogen-activated protein kinases protects against noise-induced and aminoglycoside-induced but not cisplatin-induced hair cell death, which suggests divergent upstream regulatory mechanisms.

12 April 2008 in Journal of the Association for Research in Otolaryngology
Verified
Journal Article
Open access
PDF file
LCLynn L. Chiu
Lynn L. Chiu
LCLisa L. Cunningham
Lisa L. Cunningham
DRDavid W. Raible
David W. Raible
EREdwin W Rubel
Edwin W Rubel
HOHenry C. Ou
Henry C. Ou
The zebrafish is a valuable model for studying hair cell development, structure, genetics, and behavior. Zebrafish and other aquatic vertebrates have hair cells on their body surface organized into a sensory system called the lateral line. These hair cells are highly accessible and easily visualized using fluorescent dyes. Morphological and functional similarities to mammalian hair cells of the inner ear make the zebrafish a powerful preparation for studying hair cell toxicity. The ototoxic potential of drugs has historically been uncovered by anecdotal reports that have led to more formal investigation. Currently, no standard screen for ototoxicity exists in drug development. Thus, for the vast majority of Food and Drug Association (FDA)-approved drugs, the ototoxic potential remains unknown. In this study, we used 5-day-old zebrafish larvae to screen a library of 1,040 FDA-approved drugs and bioactives (NINDS Custom Collection II) for ototoxic effects in hair cells of the lateral line. Hair cell nuclei were selectively labeled using a fluorescent vital dye. For the initial screen, fish were exposed to drugs from the library at a 100-μM concentration for 1 h in 96-well tissue culture plates. Hair cell viability was assessed in vivo using fluorescence microscopy. One thousand forty drugs were rapidly screened for ototoxic effects. Seven known ototoxic drugs included in the library, including neomycin and cisplatin, were positively identified using these methods, as proof of concept. Fourteen compounds without previously known ototoxicity were discovered to be selectively toxic to hair cells. Dose–response curves for all 21 ototoxic compounds were determined by quantifying hair cell survival as a function of drug concentration. Dose–response relationships in the mammalian inner ear for two of the compounds without known ototoxicity, pentamidine isethionate and propantheline bromide, were then examined using in vitro preparations of the adult mouse utricle. Significant dose-dependent hair cell loss in the mouse utricle was demonstrated for both compounds. This study represents an important step in validating the use of the zebrafish lateral line as a screening tool for the identification of potentially ototoxic drugs.